Literature DB >> 22302264

Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.

Masaaki Motoori1, Masahiko Yano, Ryu Ishihara, Sachiko Yamamoto, Yoshifumi Kawaguchi, Koji Tanaka, Kentaro Kishi, Isao Miyashiro, Yoshiyuki Fujiwara, Tatsushi Shingai, Shingo Noura, Masayuki Ohue, Hiroaki Ohigashi, Satoaki Nakamura, Osamu Ishikawa.   

Abstract

BACKGROUND: Esophagectomy remains the mainstay treatment for clinical T1bN0M0 esophageal cancer because pathologic lymph node metastases in these patients are not negligible. Recently, chemoradiotherapy (CRT), which can preserve the esophagus, has been reported to be a promising therapeutic alternative to esophagectomy. However, to our knowledge, no comparative studies of esophagectomy and CRT have been reported in clinical T1bN0M0 esophageal cancer.
METHODS: A total of 173 patients with clinical T1bN0M0 squamous cell carcinoma of the thoracic esophagus were enrolled in this study, 102 of whom were treated with radical esophagectomy (S group) and 71 with definitive CRT (CRT group). Treatment results of both groups were retrospectively compared.
RESULTS: No statistically significant difference was found in overall survival, but the S group displayed significantly better progression-free survival than the CRT group. Disease recurrence was observed in 12 S group patients and 20 CRT group patients. The incidence of distant recurrence was similar, while local recurrence and lymph node recurrence were significantly more frequent in the CRT group. In the S group, 20 patients had pathologic lymph node metastasis. The progression-free survival of patients with pathologic lymph node metastasis did not differ from those without nodal metastasis. In the CRT group, local recurrence could be controlled by salvage esophagectomy, but treatment results of lymph node recurrence were poor; only 4 of 12 patients with lymph node recurrences were cured.
CONCLUSIONS: Selection of patients at high risk of pathologic lymph node metastasis is essential when formulating treatment decisions for clinical T1bN0M0 esophageal cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302264     DOI: 10.1245/s10434-012-2231-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  Laparoscopic-assisted Esophageal Bypass for T4b Esophageal Tumor as a Bridge to Definitive Therapy.

Authors:  Spyridon Davakis; Athanasios Syllaios; Efstratia Mpaili; Theodoros Liakakos; Alexandros Charalabopoulos
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  Definitive chemoradiotherapy.

Authors:  Michael Stahl; Wilfried Budach
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Surgical treatments for esophageal cancers.

Authors:  William H Allum; Luigi Bonavina; Stephen D Cassivi; Miguel A Cuesta; Zhao Ming Dong; Valter Nilton Felix; Edgar Figueredo; Piers A C Gatenby; Leonie Haverkamp; Maksat A Ibraev; Mark J Krasna; René Lambert; Rupert Langer; Michael P N Lewis; Katie S Nason; Kevin Parry; Shaun R Preston; Jelle P Ruurda; Lara W Schaheen; Roger P Tatum; Igor N Turkin; Sylvia van der Horst; Donald L van der Peet; Peter C van der Sluis; Richard van Hillegersberg; Justin C R Wormald; Peter C Wu; Barbara M Zonderhuis
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

4.  Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy.

Authors:  Takahito Sugase; Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Tadayoshi Hashimoto; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Masayuki Mano; Eiichi Morii; Masaki Mori; Yuichiro Doki
Journal:  Esophagus       Date:  2018-06-16       Impact factor: 4.230

5.  The influence of adjuvant radiation therapy after endoscopic resection on survival for early stage EC: an analysis of the surveillance epidemiology and end results (SEER) database.

Authors:  Baofu Chen; Junhong Lin; Yuhang Ruan; Zixuan Chen; Kaya Petersen; Min Kong; Jianfei Shen; Gongchao Wang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer.

Authors:  Gen Kawaguchi; Ryuta Sasamoto; Eisuke Abe; Atsushi Ohta; Hiraku Sato; Kensuke Tanaka; Katsuya Maruyama; Motoki Kaizu; Fumio Ayukawa; Nobuko Yamana; Junyang Liu; Manabu Takeuchi; Masaaki Kobayashi; Hidefumi Aoyama
Journal:  Radiat Oncol       Date:  2015-01-31       Impact factor: 3.481

7.  Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan.

Authors:  Hui-Shan Chen; Wei-Heng Hung; Jiunn-Liang Ko; Po-Kuei Hsu; Chia-Chuan Liu; Shiao-Chi Wu; Ching-Hsiung Lin; Bing-Yen Wang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma.

Authors:  Hongbo Zhao; Kazuo Koyanagi; Ken Kato; Yoshinori Ito; Jun Itami; Hiroyasu Igaki; Yuji Tachimori
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

9.  Clinical practice guideline for endoscopic resection of early gastrointestinal cancer.

Authors:  Chan Hyuk Park; Dong-Hoon Yang; Jong Wook Kim; Jie-Hyun Kim; Ji Hyun Kim; Yang Won Min; Si Hyung Lee; Jung Ho Bae; Hyunsoo Chung; Kee Don Choi; Jun Chul Park; Hyuk Lee; Min-Seob Kwak; Bun Kim; Hyun Jung Lee; Hye Seung Lee; Miyoung Choi; Dong-Ah Park; Jong Yeul Lee; Jeong-Sik Byeon; Chan Guk Park; Joo Young Cho; Soo Teik Lee; Hoon Jai Chun
Journal:  Intest Res       Date:  2020-10-13

10.  Photon Versus Proton Beam Therapy for T1-3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis.

Authors:  Yang-Gun Suh; Unurjargal Bayasgalan; Heung Tae Kim; Jong Mog Lee; Moon Soo Kim; Youngjoo Lee; Doo Yeul Lee; Sung Uk Lee; Tae Hyun Kim; Sung Ho Moon
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.